Ipca Laboratories Ltd
Pharmaceuticals & Biotechnology | Mid Cap
Ipca Laboratories demonstrates a mixed financial performance. The company shows strong solvency due to a high equity ratio and minimal debt. Growth prospects appear promising, driven by robust revenue, operating profit, and EPS growth rates. However, certain areas need attention, particularly liquidity, which is currently weak. While profitability metrics such as gross profit margin, ROCE, and ROA are good, some financial metrics like adjusted EPS and net margin need improvement. The company's efficiency in utilizing assets is inconsistent, with a strong capital turnover ratio but weak fixed asset and inventory turnover. Overall, Ipca Laboratories exhibits potential for continued growth and profitability, but must address its liquidity and efficiency challenges to realize its full potential.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio6.00
- Profitability Ratio7.20
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursNeutral
- 1 DayBearish
- 1 WeekBullish
- 1 MonthNeutral
Ipca Laboratories demonstrates a mixed financial performance. The company shows strong solvency due to a high equity ratio and minimal debt. Growth prospects appear promising, driven by robust revenue, operating profit, and EPS growth rates. However, certain areas need attention, particularly liquidity, which is currently weak. While profitability metrics such as gross profit margin, ROCE, and ROA are good, some financial metrics like adjusted EPS and net margin need improvement. The company's efficiency in utilizing assets is inconsistent, with a strong capital turnover ratio but weak fixed asset and inventory turnover. Overall, Ipca Laboratories exhibits potential for continued growth and profitability, but must address its liquidity and efficiency challenges to realize its full potential.
Overall Valuation Score
P/E RATIO (TTM)
35.52
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
35.26
P/B RATIO
4.99
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
4.30
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
47.64
EV/EBITDA RATIO
19.88
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1585.8 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth prospects. The company benefits from robust revenue growth, operating profit growth, and EPS growth rates. This indicates a healthy expansion in its core business and profitability. The company's growth trajectory positions it favorably for future success and value creation. However, the company should ensure that this growth is sustainable and well-managed to maintain its financial health.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 7.45 | 7.02 | 23.5 | 16.12 | 8.42 |
| Operating Profit Growth Rate | -14.63 | -29.66 | 42.06 | 30.74 | 14.33 |
| Earnings Per Share (EPS) Growth | -22.45 | -46.69 | 16.09 | 34.82 | 54.68 |
| Asset Growth Rate | 25.65 | 13.13 | 28.69 | 5.83 | 5.33 |
| Net Income Growth Rate | -22 | -46.18 | 9.19 | 50.1 | 50.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial health presents a somewhat mixed picture. While book value per share and capital expenditure are good, adjusted EPS needs improvement. This suggests that the company has a solid foundation, but its ability to generate earnings for its shareholders needs attention. The company should focus on improving its overall financial performance to enhance shareholder value.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 35.88 | 18.8 | 21.8 | 37.96 | 51.6 |
| Cash Earnings Per Share (Cash EPS) | 44.88 | 29.64 | 35.2 | 47.32 | 64.08 |
| Book Value Per Share | 218.56 | 233.68 | 253.28 | 277.92 | 322.52 |
| Dividend Per Share (DPS) | 3.83 | 4.09 | 4.1 | 4.07 | 0 |
| Capital Expenditures (CapEx) | 476 | 458 | 402 | 771 | 317 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates strong profitability. Positive profitability metrics include gross profit margin, ROCE, and ROA. However, net profit margin needs improvement. This suggests efficient core operations but potential challenges in managing overall expenses. Enhancing net profit margin while sustaining other profitability metrics can further improve the company's financial performance.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.85 | 10.8 | 12.62 | 14.98 | 16.18 |
| Return on Capital Employed (ROCE) | 20 | 11 | 13 | 15 | 17 |
| Return on Equity (ROE) | 16.29 | 8.2 | 8.26 | 11.3 | 14.68 |
| Return on Assets (ROA) | 17.38 | 10.81 | 11.93 | 14.74 | 16 |
| Operating Margin | 22.86 | 15.02 | 17.28 | 19.46 | 20.52 |
| Net Margin | 15.35 | 7.72 | 6.83 | 8.82 | 12.27 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in utilizing its assets is mixed. While capital turnover is good, fixed asset and inventory turnover need improvement. This suggests that the company could optimize its asset management practices to enhance operational efficiency. Efficient asset utilization can lead to cost savings, improved profitability, and enhanced shareholder value. There are definitely areas of Improvement for the Company.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.41 | 2.26 | 1.68 | 2.09 | 2.08 |
| Inventory Turnover Ratio | 2.72 | 3.07 | 3.18 | 3.01 | 3.06 |
| Receivables Turnover Ratio | 6.73 | 6.53 | 5.73 | 5 | 4.96 |
| Days Sales in Inventory Ratio | 134.19 | 118.89 | 114.78 | 121.26 | 119.28 |
| Receivable Days | 54.23 | 55.9 | 63.7 | 73 | 73.59 |
| Capital Turnover Ratio | 0.99 | 0.95 | 1.1 | 1.18 | 1.17 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates adequate coverage of its financial obligations. The interest coverage ratio is strong, but the equity dividend coverage ratio is weak. This suggests that the company can comfortably meet its interest expenses but may face challenges in covering its dividend payments with equity. The company should manage its coverage ratios prudently to maintain financial stability.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 104.27 | 16.52 | 6.98 | 13.85 | 21.7 |
| Equity Dividend Coverage Ratio | 9.09 | 4.55 | 5.26 | 7.14 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency. This indicates a solid financial structure and a low risk of financial distress. The company benefits from a high equity base and minimal reliance on debt financing. This provides stability and flexibility in managing its long-term financial obligations. The company's financial strength allows it to pursue growth opportunities and withstand economic downturns effectively.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.07 | 0.1 | 0.09 | 0.08 | 0.03 |
| Debt to Equity Ratio | 0.08 | 0.11 | 0.1 | 0.09 | 0.03 |
| Equity Ratio | 0.93 | 0.9 | 0.91 | 0.92 | 0.97 |
| Debt To Asset Ratio | 0.05 | 0.08 | 0.06 | 0.05 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is concerning. This suggests potential difficulties in meeting short-term obligations. Low liquidity can restrict operational flexibility and increase financial risk, particularly in unforeseen circumstances. The company may face challenges in funding immediate expenses and capitalizing on short-term investment opportunities. However, the company should improve its ability to convert assets into cash and better manage its short-term liabilities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.25 | 2.42 | 1.29 | 1.4 | 1.5 |
| Quick Ratio | 1.18 | 1.6 | 0.69 | 0.79 | 0.83 |
| Cash Ratio | 0.37 | 0.88 | 0.07 | 0.08 | 0.14 |
| Operating Cash Flow Ratio | 0.49 | 0.38 | 0.23 | 0.32 | 0.28 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 11 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 12 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 13 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 14 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 15 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 16 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 17 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
The management of Ipca Laboratories shows a mixed performance. Revenue growth is strong, as seen in the compounded sales growth and recent quarterly improvements. However, profit growth has been inconsistent, with notable fluctuations in quarterly net profits and a recent dip. While the company demonstrates reasonable capital efficiency, its increasing debt levels raise concerns about its long-term financial stability. Promoter holding is stable but has slightly decreased recently. Overall, the inconsistencies in profitability and rising debt warrant caution.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (TTM) | 17% | Strong revenue expansion |
| Promoter Holding (Mar 2025) | 44.72% | Indicates confidence and alignment | |
| CONS | YOY Profit Growth (Mar 2025) | 180% | Volatile profit growth |
| Debt/Equity Ratio | Increasing Borrowings | Leverage is increasing |
Financial Performance & Growth
Ipca Laboratories demonstrates mixed financial performance. Compounded sales growth shows a positive trend. However, profit growth has been volatile, particularly in recent quarters, with significant fluctuations in quarterly net profits. Despite sales growth, the volatility in profit growth raises concerns about consistency.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Compounded Sales Growth | 8.6% | 9.5% | 7.03% | 23.50% | 16.67% |
| Compounded Profit Growth | 32.8% | 14.3% | -34.5% | -19.3% | 52% |
Capital Efficiency & Returns
Ipca Laboratories maintains reasonable capital efficiency. The Return on Capital Employed (ROCE) and Return on Equity (ROE) reflect the company's ability to generate returns from its capital and shareholder funds. However, there has been a decline in ROCE over the years. The company's asset turnover indicates how effectively it converts assets into revenue.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Average ROCE (%) | 15.77 | 11.67 | 20 | 11 | 13 | 15 | | Average ROE (%) | 11.19 | 11.89 | 20 | 8.68 | 8.68 | 8.68 |
Financial Health & Prudence
Ipca Laboratories shows concerning trends in financial health. The company's borrowings have increased over the years, leading to higher debt levels. Although the interest coverage ratio has fluctuated, the rising debt could pose risks if profitability declines. The dividend payout indicates a consistent sharing of profits, but the increasing debt load needs careful management.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Average Borrowings (₹ Cr) | 768.33 | 603 | 524.33 | 1481 | 1438 | 1363 | | Interest Coverage Ratio (Avg PBT/Interest) | 14.31 | 13.68 | 67.18 | 15.52 | 5.98 | 13.31 |
Shareholding & Ownership Structure
Ipca Laboratories has a relatively stable shareholding pattern. Promoter holding remains significant. Institutional holding by FIIs and DIIs suggests that the company is attractive to institutional investors.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 46.13 | 46.07 | 46.29 | 46.29 | 44.72 |
| FII Holding (%) | 15.55 | 14.87 | 17.47 | 10.58 | 10.75 |
| DII Holding (%) | 21.70 | 24.88 | 24.82 | 33.74 | 35.73 |
The risk assessment for Ipca Laboratories reveals a moderate level of concern due to segment performance volatility and increasing working capital days. The company's exposure to foreign exchange or interest rate fluctuations, coupled with rising regulatory compliance costs, could further strain profitability. The increasing borrowings also add financial risk. Overall, the company faces notable operational and financial risks that require careful monitoring and strategic mitigation.
Segment performance volatility
The quarterly results indicate some volatility in segment performance, with fluctuations in YOY Sales Growth % and YOY Profit Growth %.
Foreign exchange or interest rate exposure
The company is exposed to foreign exchange or interest rate fluctuations, which could impact profitability.
Regulatory compliance cost trends
Regulatory compliance costs appear to be increasing, which could strain profitability.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101578.89Bullish
- SMA 201558.72Bullish
- SMA 501576.63Bullish
- EMA 101580.20Bullish
- EMA 201571.12Bullish
- EMA 501575.32Bullish
- DEMA 101594.39Bearish
- DEMA 201577.47Bullish
- DEMA 501564.49Bullish
- TEMA 101599.33Bearish
- TEMA 201592.87Bearish
- TEMA 501559.22Bullish
- MACD6.97Bullish
- ADX29.44Strong Trend
- IndicatorValueSignal
- RSI60.28Neutral
- CCI89.91Neutral
- ROC 93.07Bullish
- ROC 142.99Bullish
- ROC 251.99Bullish
- Stoch K73.41Neutral
- Stoch D80.24Overbought
- IndicatorValueSignal
- BB Upper1611.61Neutral
- BB Middle1558.73Neutral
- BB Lower1505.84Neutral
- ATR14.82High Volatility
- IndicatorValueSignal
- MFI71.33Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101561.62Bullish
- SMA 201560.32Bullish
- SMA 501596.89Bearish
- EMA 101571.92Bullish
- EMA 201571.11Bullish
- EMA 501579.60Bullish
- DEMA 101581.27Bullish
- DEMA 201563.98Bullish
- DEMA 501574.21Bullish
- TEMA 101594.60Bearish
- TEMA 201568.76Bullish
- TEMA 501562.76Bullish
- MACD-3.11Bullish
- ADX18.39Weak Trend
- IndicatorValueSignal
- RSI56.02Neutral
- CCI97.78Neutral
- ROC 93.45Bullish
- ROC 142.46Bullish
- ROC 25-1.52Bearish
- Stoch K78.76Neutral
- Stoch D77.25Neutral
- IndicatorValueSignal
- BB Upper1605.12Neutral
- BB Middle1560.33Neutral
- BB Lower1515.53Neutral
- ATR20.17Low Volatility
- IndicatorValueSignal
- MFI51.51Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101560.79Bullish
- SMA 201594.13Bearish
- SMA 501592.15Bearish
- EMA 101572.17Bullish
- EMA 201578.38Bullish
- EMA 501578.32Bullish
- DEMA 101566.50Bullish
- DEMA 201570.64Bullish
- DEMA 501590.86Bearish
- TEMA 101571.53Bullish
- TEMA 201562.11Bullish
- TEMA 50N/AN/A
- MACD-6.46Bearish
- ADX19.81Weak Trend
- IndicatorValueSignal
- RSI52.45Neutral
- CCI-11.36Neutral
- ROC 90.86Bullish
- ROC 14-2.26Bearish
- ROC 253.54Bullish
- Stoch K42.84Neutral
- Stoch D25.61Neutral
- IndicatorValueSignal
- BB Upper1673.23Neutral
- BB Middle1594.13Neutral
- BB Lower1515.02Neutral
- ATR31.63High Volatility
- IndicatorValueSignal
- MFI34.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101596.03Bearish
- SMA 201580.60Bearish
- SMA 501547.35Bearish
- SMA 1001520.78Bullish
- SMA 2001452.58Bullish
- EMA 101573.01Bearish
- EMA 201576.59Bearish
- EMA 501558.12Bearish
- EMA 1001526.36Bullish
- EMA 2001485.97Bullish
- DEMA 101560.16Bearish
- DEMA 201581.65Bearish
- DEMA 501592.08Bearish
- DEMA 1001581.27Bearish
- DEMA 2001546.56Bearish
- TEMA 101545.48Bearish
- TEMA 201569.13Bearish
- TEMA 501593.11Bearish
- TEMA 1001599.42Bearish
- TEMA 2001565.90Bearish
- MACD1.18Bearish
- ADX19.08Weak Trend
- IndicatorValueSignal
- RSI44.19Neutral
- CCI-77.92Neutral
- ROC 141.26Bullish
- ROC 252.48Bullish
- Stoch K37.08Neutral
- Stoch D43.11Neutral
- IndicatorValueSignal
- BB Upper1671.35Neutral
- BB Middle1580.60Neutral
- BB Lower1489.85Neutral
- ATR49.10Low Volatility
- IndicatorValueSignal
- MFI58.17Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 201523.99Bullish
- SMA 501454.20Bullish
- EMA 201532.60Bullish
- EMA 501478.04Bullish
- DEMA 201584.55Bearish
- DEMA 501544.76Bullish
- TEMA 201600.24Bearish
- TEMA 501552.62Bullish
- MACD39.51Bullish
- ADX31.22Strong Trend
- IndicatorValueSignal
- RSI54.56Neutral
- CCI150.89Overbought
- ROC 145.94Bullish
- ROC 2511.10Bullish
- Stoch K63.98Neutral
- Stoch D64.92Neutral
- IndicatorValueSignal
- BB Upper1650.79Neutral
- BB Middle1523.99Neutral
- BB Lower1397.19Neutral
- ATR110.77Low Volatility
- IndicatorValueSignal
- MFI82.20Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61512.52Bullish
- SMA 121448.88Bullish
- SMA 241444.17Bullish
- EMA 61509.80Bullish
- EMA 121473.54Bullish
- EMA 241402.31Bullish
- DEMA 61546.78Bearish
- DEMA 121533.57Bearish
- DEMA 241546.14Bearish
- TEMA 61553.53Bearish
- TEMA 121531.88Bearish
- TEMA 241543.61Bearish
- MACD182.00Bearish
- ADX33.45Strong Trend
- IndicatorValueSignal
- RSI58.06Neutral
- CCI99.83Neutral
- ROC 2513.80Bullish
- ROC 5043.04Bullish
- Stoch K57.10Neutral
- Stoch D67.63Neutral
- IndicatorValueSignal
- BB Upper1663.08Neutral
- BB Middle1466.98Neutral
- BB Lower1270.88Neutral
- ATR185.33High Volatility
- IndicatorValueSignal
- MFI57.58Neutral